NMN FDA Response Delayed – What This Means for the Future of NAD+ Supplements

FDA Delays NMN Citizen Petition Response: What We Know So Far

In July 2025, the U.S. Food and Drug Administration (FDA) officially confirmed that its response to the NMN citizen petition has been postponed due to internal staffing shortages^[1]. Initially filed in late 2022, the petition seeks regulatory clarity on whether nicotinamide mononucleotide (NMN) can be marketed as a dietary supplement in the United States.

In the world of NAD⁺ boosters, both domestic and international NMN manufacturers are facing uncertainty. Many companies, particularly those providing the best NMN powder formulations, are awaiting the FDA’s upcoming decision to adapt their market strategies. This regulatory ambiguity has important implications for product development, branding, and international supply chains.

For details on current legal progress, see Effepharm’s NMN Legal Dispute Update.

The Legal Background: NMN, Drug Classification, and Supplement Status

The core issue surrounding NMN’s legality is not safety—NMN has a long-standing reputation for being well tolerated and effective—but classification. According to the Dietary Supplement Health and Education Act of 1994 (DSHEA), ingredients that have been authorized for investigation as drugs prior to being marketed cannot be sold as dietary supplements.

This clause lies at the center of the FDA’s hesitation. NMN, which has been studied for its therapeutic potential, now exists in a grey area between dietary supplements and pharmaceuticals. Nevertheless, years of safe global use and scientific support continue to reinforce NMN’s credibility.

Instead of market disruption, the regulatory suspension has changed consumer behavior. A lot of health-conscious consumers are now energetically investigating other NAD⁺ precursors, particularly since platforms like Amazon US decided to remove NMN products from their listings before receiving legal clarification. When NMN supplements have been limited on primary distribution channels such as Amazon US, the consumer interest has shifted prominently toward the next-generation NAD⁺ boosters. The sales of NMNH in the U.S. anti-aging market went up 1220% from 2023 to 2024, and liposomal NAD⁺ also gained a 324% increase, which is a very substantial growth, according to the Meritco Services Report. This dramatic rise makes it clear that a strong trend is emerging: customers are choosing more advanced and more easily absorbed NAD⁺-based solutions for the period of regulatory doubts.

To explore regulatory implications further, visit NMN at a Crossroads.

What Might Happen in September? Scenarios for Brands and Consumers

Effepharm’s internal analysis identifies two potential outcomes expected from the FDA in September:

• If the FDA permits NMN to maintain its status as a dietary supplement, brands will regain full legal clarity and can resume broader marketing and distribution efforts.
• If the FDA classifies NMN as a drug, it may be restricted to pharmaceutical channels, limiting consumer access and altering the competitive landscape.

This upcoming regulatory decision is likely to have a strong impact on companies involved in NMN production and formulation, particularly those with a presence in the U.S. and European markets. Depending on the outcome, brands may need to act quickly—either to resume work on NMN-based products or to shift their focus toward other NAD⁺ support solutions. The ruling could also influence how products are labeled, transported across borders, and made available to consumers worldwide.

UthPeak® NMNH: A Potent Alternative with 10x Potential

With the uncertainty surrounding NMN, reduced NMN, or NMNH, is attracting attention as a next-generation NAD⁺ booster. Effepharm’s UthPeak® NMNH offers a more clinically proven advanced solution with enhanced potency and fewer legal complexities.

Scientific evidence suggests that NMNH provides significantly higher NAD⁺ bioavailability than NMN. In a 2021 study, reduced NMN (NMNH) demonstrated markedly improved NAD⁺ elevation in cells compared to NMN, while also suppressing metabolic overactivation^[2].

Comparison Snapshot:

• NMN:Clinically supported, widely known, but under legal evaluation for its classification in the US.
• NMNH:Not classified as a drug, 10x NAD⁺ increase in preclinical models, aligns with current U.S. regulations.

With its superior stability and uptake efficiency, UthPeak® NMNH aligns perfectly with the evolving demands of supplement brands and consumers focused on cellular energy and longevity.

Liposomal NAD⁺: Rising Popularity Amid Regulatory Shifts

The liposomal NAD⁺ has become a rival to traditional NMN supplements, which are going to be less and less trusted. The new type of delivery exploits the technology of liposomes to basically make the NAD⁺ more absorbable and available at the cellular level, thus solving the issues of digestive breakdown and bioavailability that are usually brought up.

A report by Meritco Services reveals that the demand for liposomal NAD⁺ in the U.S. anti-aging supplement market soared by 324%, from 2023 to 2024, indicating that consumers trust delivery systems of the next generation. The market trend is that liposome-based formulations are becoming progressively popular because they are supported by scientific research and meet changing customer needs, as more consumers focus on the need for effective and quick NAD⁺ boosters.

Choose Next-Gen NAD⁺ Boosters with Regulatory Clarity

Under existing U.S. regulations, NMN is still available and continues to assist consumers who want reliable NAD⁺ enhancement. Effepharm’s UTHEVER^® NMN remains a leading choice for those seeking high-quality NMN powder with proven safety and purity. Looking ahead, innovation is essential. Effepharm is actively broadening its range of advanced NAD⁺ solutions, including UthPeak^® NMNH, which offers improved effectiveness via the NMNH pathway. With clear legal guidelines and scientific support, these next-generation supplements enable brands to stay competitive while providing consumers with confidence in their health decisions.

References：

[1] NutraIngredients-USA. (2025, July 29). Short-staffed FDA delays response to NMN citizen petition. Retrieved from https://www.nutraingredients-usa.com/Article/2025/07/29/short-staffed-fda-delays-response-to-nmn-citizen-petition

[2] Liu, Y., Luo, C., Li, T., Zhang, W., Zong, Z., Liu, X., & Deng, H. (2021). Reduced nicotinamide mononucleotide (NMNH) potently enhances NAD+ and suppresses glycolysis, the TCA cycle, and cell growth. Journal of Proteome Research, 20(5), 2596– https://doi.org/10.1021/acs.jproteome.0c01037